The United Kingdom and the United States have signed a key bilateral deal that will keep no duties on UK drug shipments going into the US market.
The Terms of the Accord
In exchange for the tariff guarantee, the UK has pledged to boost spending on pharmaceuticals through the public health system. This move ensures that tariffs on these crucial goods will be held at zero for a timeframe of the next three years.
This deal follows earlier statements to hike duties on branded drug products, with increases floated up to double the cost.
"This arrangement with the United Kingdom strengthens the international landscape for new treatments and introduces much-needed fairness to U.S.–U.K. drug exports," a statement declared.
Economic Impact
Pharmaceuticals are one of the UK's largest goods shipped to the US, which is easily the primary market for major UK drugmakers.
Export figures reveal that in the one-year period to the end of September, the UK sold medicines valued at billions to the US. This figure made up nearly one-fifth of total UK exports in that span.
"This deal secures employment, increases investment and facilitates the UK to become a worldwide center for life sciences," the Business and Trade Secretary commented.
Specific UK Commitments
The deal entails several key commitments from the United Kingdom:
- Higher Cost Ceiling: The UK will lift the price threshold at which it considers new medicines to be too expensive by 25%.
- Higher Drug Budget: There is a goal to double overall NHS spending on medicines from 0.3% of the national economy to 0.6 percent over the following ten-year period.
- Rebate Cap: The percentage drug companies must refund to the NHS to prevent overspending will be limited at 15%. Last year, refunds topped twenty percent.
Recent Tensions
This agreement takes place against a long-running tension between the pharmaceutical industry and the British authorities over spending levels and regulatory access.
The disagreement were heightened by claims that US consumers were charged significantly more for the same drugs than people in the Britain and the EU.
In recent months, several significant manufacturing plans in the UK have been halted or abandoned, while substantial funding commitments have been directed toward projects in the United States.
A senior figure stated that the NHS had to invest a greater share on drugs, noting that its budget allocation on drugs had decreased as a share of its total funding over the last ten years.
